After 9 years of fruitless work on treatments for Alzheimer's disease and depression, AstraZeneca is dissolving its partnership with Targacept, leaving the battered biotech to pick up the pieces of its dwindling pipeline.
It's one step back, one step forward for AstraZeneca's key respiratory drug benralizumab.
After acknowledging a midstage setback for its key respiratory drug benralizumab in COPD last month, AstraZeneca's big MedImmune division has come back with positive, though somewhat mixed, Phase IIb data underscoring the effectiveness of knocking down eosinophils--white blood cells--in preventing asthma attacks.
Ever since Pascal Soriot took the reins at AstraZeneca, he's been talking up Brilinta as a diamond in the rough. With some work, the clot-fighting drug really could become a blockbuster, the CEO figures. No, really.
Fresh off an IPO, Ardelyx reports that its lead drug tenapanor (RDX5791) scored a success in a large Phase IIb trial for irritable bowel syndrome. And that counts as a win for AstraZeneca, which signed a $272 million partnership deal on the drug back in 2012--part of a deal frenzy aimed at repairing a damaged pipeline.
AstraZeneca is looking to bring more of its IT work in-house, spending money to stand up an Indian hub that will replace much of its contract spend in the field.
Over the weekend oncology investigators from all around the world gathered in Madrid at the European Society for Medical Oncology (ESMO) 2014 Congress to review the latest advances--and setbacks--in the fast-moving field of cancer drug research. As usual, the big companies dominated the discussions, as rival oncology groups touted new data as they tried to position competing therapies in the global scramble to develop new and better cancer drugs, now one of the hottest fields in R&D.
When Europe's drug approval gatekeepers meet, they often tick off recommendations for some key Big Pharma products. This week, the Committee for Medicinal Products for Human Use backed a whopping 15 new meds and 3 new indications.
Talk about selling off old products. AstraZeneca has unloaded 18 drugs it no longer sells to specialty generics maker IGI Laboratories. Apparently, IGI thinks it can profit from reintroducing meds that weren't worth the trouble for a drug giant.
Some companies, like Hikma, have had great success targeting drugs on the FDA shortage list, getting them to market and reaping the premium pricing that comes from supplying pent-up demand. Now IGI Laboratories has plans to do the same, having picked up 17 currently retired injectable drugs from AstraZeneca, nearly half of which are on the FDA list.